Warnings and Precautions Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, ...
A convenient guide for the preparation, mixing, and administration of Sandostatin® LAR Depot (octreotide acetate) for injectable suspension.
A guide to identifying and managing the 5E's (Eating, Exercising, Emotions, Epinephrine, and Ethanol), potential triggers of the severe diarrhea and flushing associated with carcinoid syndrome.
A comprehensive guide for nurses, featuring information about dosing, administration, symptom management, testing, and patient support for Sandostatin LAR Depot.
Contact a Clinical Educator (CE) for an in-office mixing and administration demonstration.
For more information, please see the Dosing & Administration section.
For more information, please see the Access section.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Please see full Prescribing Information.
Indications and Usage
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.